Section Arrow
MRNA.NASDAQ
- Moderna
Quotes are at least 15-min delayed:2025/01/12 06:13 EST
Last
 42.25
-0.92 (-2.13%)
Day High 
43.6999 
Prev. Close
43.17 
1-M High
48.92 
Volume 
6.41M 
Bid
42.23
Ask
42.39
Day Low
41.785 
Open
42.765 
1-M Low
37.44 
Market Cap 
16.61B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 41.92 
20-SMA 41.39 
50-SMA 43.78 
52-W High 170.47 
52-W Low 35.8 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-5.81/-6.58
Enterprise Value
17.83B
Balance Sheet
Book Value Per Share
30.99
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
6.75B
Operating Revenue Per Share
23.62
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CDTConduit Pharmaceuticals0.1233+0.0413+50.37%-- 
MRSNMersana Therapeutics0.72-0.58-44.62%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.2787+0.0227+8.87%-- 
ZVSAZyVersa Therapeutics1.47+0.29+24.58%0PE
SANASana Biotechnology3.66-0.64-14.88%-- 
Quotes are at least 15-min delayed:2025/01/12 06:13 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.